Mitochondria as target for antiischemic drugs

Advanced Drug Delivery Reviews

Volumn 49, Issue 1-2, 2001, Pages 151-174

  Morin, Didier ^a   Hauet, Thierry ^b   Spedding, Michael ^c   Tillement, Jean Paul ^a  

^a CNRS   (France)

^b CEMAGREF   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antioxidant; Ca2+ overload; Ischemia; Mitochondrial metabolism; Mitochondrial transition pore; Reperfusion

Indexed keywords

BLOOD; CALCIUM; CELLS; FREE RADICALS; HYDROGEN; IONIZATION;

MITOCHONDRIA;

DRUG THERAPY;

2 OXOGLUTARIC ACID; 2,4 DINITROPHENOL; 5 HYDROXYDECANOIC ACID; 7 CHLORO 5 (2 CHLOROPHENYL) 1,5 DIHYDRO 4,1 BENZOTHIAZEPIN 2(3H) ONE; AMIODARONE; BENZOTHIAZEPINE DERIVATIVE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CLONAZEPAM; DIAZOXIDE; DICHLOROACETIC ACID; DILTIAZEM; ENZYME INHIBITOR; ETOMOXIR; ISOCITRIC ACID; MENADIONE; OXFENICINE; PERHEXILINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; RANOLAZINE; RIBOFLAVIN; RUTHENIUM RED; SUCCINIC ACID; SULBUTIAMINE; THIAMINE; TRIMETAZIDINE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL PROTECTION; HUMAN; ISCHEMIA; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TARGET CELL;

EID: 0035797127     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00132-6     Document Type: Article

References (229)

1. The role of mitochondria in the salvage and the injury of the ischemic myocardium
2. Mitochondria in neurodegeneration: Acute ischemia and chronic neurodegenerative diseases
3. Mitochondria, oxidative stress and aging
4. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right think?
5. Development of HU-211 as a neuroprotectant for ischemic brain damage
6. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy
7. The mitochondrial permeability transition
8. The mitochondrial permeability transition pore and its role in cell death
9. Pathophysiology of ischemia: An overview
10. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potentials for pharmacological interventions
11. Glutamate in neurologic diseases
12. Real-time measurement of ischemia-evoked glutamate release in the cerebral cortex of four and eleven vessel rat occlusion models
13. Modeling of internal pH, ion concentration, and bioenergetic changes during myocardial ischemia
14. Extracellular acidosis delays onset of cell in ATP-depleted hepatocytes
15. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate
16. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane
17. Therapeutic approaches for clinical ischemia and reperfusion injury
18. Relation of mitochondrial and cytosolic free calcium to cardiac myocyte recovery after exposure to anoxia
19. Changes in mitochondrial matrix free calcium in perfused rat hearts subjected to hypoxia-reoxygenation
20. The role of mitochondria in ischemic heart disease
21. Free radical metabolites in myocardium during ischemia and reperfusion
22. 2+ transport and oxidative damage of mitochondria
23. Ischemia-induced neuronal apoptosis
24. Apoptosis in the failing human heart
25. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis
26. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver
27. Control of apoptosis by the cellular ATP level
28. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis
29. Role of lipids and lipids metabolites in myocardial ischemia
30. Trimetazidine: Experimental and clinical update review
31. Antiischemic effect of trimetazidine: P-31 NMR spectroscopy in the isolated rat heart
32. Trimetazidine, a cellular anti-ischemic agent
33. Effect of trimetazidine on mitochondrial functions and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium
34. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function
35. Some biological aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation
36. Ionic and metabolic imbalance as potential factors of ischemic injury
37. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart
38. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acids oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl Coenzyme A thiolase
39. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia
40. The pH-partition profile of the antiischemic drug trimetazidine may explain its reduction of intracellular acidosis
41. Ranolazine: A metabolic modulator for the treatment of angina
42. Antianginal effects of ranolazine in various experimental models of angina
43. Protective effect of ranolazine in guinea pig hearts during low flow ischemia and their association with increases in active pyruvate dehydrogenase
44. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for indirect mechanism
45. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart
46. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids
47. The pharmacology of dichloroacetate
48. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group
49. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts
50. Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium
51. Dichloroacetate as metabolic therapy for myocardial ischemia and failure
52. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate
53. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease
54. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders
55. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heart
56. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir
57. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine
58. Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia
59. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris
60. Protection of the ischaemic dog heart by oxfenicine
61. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir
62. Inhibition of carnitine palmytoyltransferase-1 in rat heart and liver by perhexiline and amiodarone
63. Dual effect of amiodarone on mitochondrial respiration initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the level of complexe I and complexe II
64. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: The possible role in pseudoalcoholic liver lesions
65. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate
66. Biochemical, physiological and medical aspects of ubiquinone function
67. Improvement of cardiac function and myocardial energy metabolism of rats with chronic heart failure by long-term coenzyme Q10 treatment
68. Improvement in recovery of left ventricular function during reperfusion with coenzyme Q10 in isolated working rat heart
69. 2+ overload during postischemic reperfusion
70. Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment
71. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials
72. Overview of the use of CoQ10 in cardiovascular disease
73. Médicaments interagissant avec les mitochondries: Effets anti-ischémiques de la trimétazidine
74. Regulation of carbohydrate metabolism in ischemia and reperfusion
75. Pyruvate: Metabolic protector of cardiac performance
76. Mechanisms by which mitochondria transport calcium
77. Role of calcium ions in regulation of mammalian intramitochondrial metabolism
78. 2+ exchange
79. 2+ exchanger
80. Protection against hypoxic injury in isolated-perfused rat heart by ruthenium red
81. m overload in rat hearts
82. 2+ to the mitochondrial permeability transition induced by tert-butylhydroperoxide in rat hepatocytes
83. + channel in the mitochondrial inner membrane
84. Mitochondria: A new target for K channel openers?
85. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology
86. The mitochondrial KATP channel as a receptor for potassium channel openers
87. Mitochondrial volume control
88. + channels modulate cardiac mitochondrial function
89. + channels. Possible mechanism of cardioprotection
90. Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection?
91. Preservation of mitochondrial function by diazoxide during sustained ischaemia in the rat heart
92. + channel in mitochondria: Pharmacology and function
93. 2+ overload in rat cardiac mitochondria
94. On the voltage dependence of the mitochondrial permeability transition pore. A critical appraisal
95. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death
96. Uncoupling: New approaches to an old problem of bioenergetics
97. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP
98. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition
99. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid
100. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
101. Control and kinetic analysis of ischemia-damaged heart mitochondria: Which parts of the oxidative phosphorylation system are affected by ischemia?
102. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria
103. Generating, partitioning, targeting and functioning of superoxide in mitochondria
104. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation
105. Mitochondria and neuronal glutamate excitotoxicity
106. Calcium-related damage in ischemia
107. The role of mitochondria in aging
108. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
109. Oxygen-mediated myocardial damage during ischaemia and reperfusion: Role of the cellular defences against oxygen toxicity
110. 2+: An alternate mechanism for the cardiotoxicity of doxorubicin
111. +: Implications for neurodegeneration
112. Ca(2+)-induced mitochondrial membrane permeabilization: Role of coenzyme Q redox state
113. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites
114. Effect of Ginkgo biloba extract (EGB 761) on the central nervous system
115. Effects of Ginkgo biloba extract on a cerebral ischemia model in gerbils
116. Efficiency of Ginkgo biloba extract (EGB 761) in antioxidant protection against myocardial ischemia and reperfusion injury
117. Ginkgo biloba extract (EGB 761): Antioxidant properties and regulation of gene expression
118. Lipid peroxide, phospholipids, glutathione levels and superoxide dismutase activity in rat brain after ischaemia: Effect of ginkgo biloba extract
119. Protection of mitochondrial respiration activity by bilobalide
120. EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation
121. Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity
122. Declines in mitochondrial respiration during cardiac reperfusion: Age-dependent inactivation of alpha-ketoglutarate dehydrogenase
123. In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides
124. Antioxidant properties of ginkgolides: Protection of testicular Leydig-cell cytochrome P-450scc activity and androgen formation
125. Wine, alcohol, platelets, and the French paradox for coronary heart disease
126. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury
127. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests
128. Effects of resveratrol on the rat brain respiratory chain
129. Effect of inhibition of the mitochondrial ATPase on net myocardial ATP in total ischemia
130. Propofol preserves the viability of isolated rat hepatocyte suspensions under an oxidant stress
131. The in vitro effects of propofol on tissular oxidative stress in the rat
132. Propofol hemisuccinate protects neuronal cells from oxidative injury
133. Propofol neuroprotection in a rat model of ischaemia reperfusion injury
134. Effect of propofol on oxidative stress in an in vitro model of anoxia-reoxygenation in the rat brain
135. Propofol improves functional and metabolic recovery in ischemic reperfused isolated rat hearts
136. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition
137. Effect of propofol on in vitro lipid peroxidation induced by different free radical generating systems: A comparison with vitamin E
138. Propofol is a peroxynitrite scavenger
139. Effects of the general anaesthetic Propofol on the Ca2(+)-induced permeabilization of rat liver mitochondria
140. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart
141. Effects of the anaesthetic propofolon the calcium-induced permeability transition of rat heart mitochondria: Direct pore inhibition and shift of the gating potential
142. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol
143. Antagonism of the inhibitory effects of adenosine 5′-triphosphate on the isolated Taenia of the guinea-pig caecum: Structure-activity relationships within a series of isatogen derivatives
144. Antagonists and the purinergic nerve hypothesis: 2,2′-pyridylisatogen tosylate (PIT), an allosteric modulator of P2Y receptors. A retrospective on a quarter century of progress
145. 2-2′-Pyridylisatogen, a selective allosteric modulator of P2 receptors, is a spin trapping agent
146. Disruption of energy metabolism by pyridylisatogen is mediated by the mitochondrial permeability in rat hepatic mitochondria
147. Glutamate-induced neuron death requires mitochondrial calcium uptake
148. Protection from cerebral ischemic injury in gerbils with the spin trap agent N-tert-butyl-alpha-phenylnitrone (PBN)
149. alpha-Phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia
150. N-tert-butyl-alpha-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia
151. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
152. Cardiac adrenergic receptor effects of carvedilol
153. Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury
154. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model
155. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism
156. Ischemic heart disease: The role of mitochondria - Carvedilol prevents lipid peroxidation of mitochondrial membranes
157. Carvedilol inhibits the exogenous NADH dehydrogenase in rat heart mitochondria
158. - release as a byproduct of respiration
159. Molecular actions of ebselen: An antiinflammatory antioxidant
160. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
161. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat
162. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion
163. Ebselen, a novel anti-oxidant compound, protects the rat liver from ischemia-reperfusion injury
164. Protection by seleno-organic compound, Ebselen, against acute gastric mucosal injury induced by ischemia-reperfusion in rats
165. Effects of ebselen on cerebral ischemia and reperfusion evaluated by microdialysis
166. Oxidative damage to mitochondria and protection by ebselen and other antioxidants
167. Effects of ebselen, a glutathione peroxidase mimic, in several models of mitochondrial dysfunction
168. The anti-oxidant ebselen antagonizes the release of the apoptogenic factor cytochrome c induced by Fe(2+)/citrate in rat liver mitochondria
169. The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition. Evidence for the participation of reactive oxygen species in this mechanism
170. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders
171. 2+-induced membrane transition in mitochondria. I. The protective mechanisms
172. 2+ trigger site
173. Action of cyclosporine A on mitochondrial calcium fluxes
174. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria
175. The mitochondrial megachannel is the permeability transition pore
176. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin A is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it from interacting with the adenine nucleotide translocase
177. The mitochondrial permeability transition pore
178. Mitochondria and cell death. Mechanistic aspects and methodological issues
179. 2+-dependent pore activated by oxidative stress in heart mitochondria
180. The mitochondrial death/life regulator in apoptosis and necrosis
181. Bcl-2 family proteins and mitochondria
182. Mitochondria as the central control point of apoptosis
183. Caspase-3 in permanent focal ischemia: More than apoptosis
184. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition
185. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A
186. 2+ cycling in cytotoxicity
187. Protection by cyclosporin A of cultured hepatocytes from the toxic consequences of the loss of mitochondrial energization produced by 1-methyl-4-phenylpyridinium
188. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide
189. Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes
190. Cyclosporin A protects against ischemia-reperfusion injury in the brain
191. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion
192. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat
193. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury
194. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria
195. Mitochondria in neurodegeneration: Bioenergetic function in cell life and death
196. Mitochondrial permeability transition in the central nervous system: Induction by calcium cycling-dependent and -independent pathways
197. Characteristics of the calcium-triggered mitochondrial permeability transition in nonsynaptic brain mitochondria: Effect of cyclosporin A and ubiquinone O
198. Cyclosporin A delays mitochondrial depolarization induced by N-methyl-d-aspartate in cortical neurons: Evidence of the mitochondrial permeability transition
199. Related cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death
200. Calcineurin and mitochondrial function in glutamate-induced neuronal cell death
201. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury
202. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart
203. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils
204. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin
205. Differences in the activation of the mitochondrial permeability transition among brain regions in the rat correlate with selective vulnerability
206. Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: Relationship between pore opening and the activity of mitochondrial phospholipases
207. 2-dependent mitochondrial swelling
208. Cyclosporine A-induced oxidative stress in rat hepatocytes
209. A ubiquinone-binding site regulates the mitochondrial permeability transition pore
210. Progress on the mitochondrial permeability transition pore: Regulation by complex I and ubiquinone analogs
211. 3H]trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore
212. The mitochondrial permeability transition. Interactions of spermine, ADP, and inorganic phosphate
213. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore
214. 3H]Trimetazidine mitochondrial binding sites: Regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance
215. Electrophysiology of the inner mitochondrial membrane
216. 2+ plus prooxidants
217. Dose-related inversion of cinnarizine and flunarizine effects on mitochondrial permeability transition
218. Energetics in the pathogenesis of neurodegenerative diseases
219. Kidney preservation ex vivo for transplantation
220. Lipid peroxidation after acute renal ischemia and reperfusion in rats: The effect of trimetazidine
221. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury rats
222. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits
223. Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats
224. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the antiischemic agent trimetazidine
225. Trimetazidine prevents renal injury in the isolated perfused pig kidney exposed to prolonged cold ischemia
226. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys
227. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine
228. Ranolazine: A new drug with beneficial effects on renal preservation